



A PERFORMANCE NOT TO BE MISSED...

Dear Healthcare Professional

July 2020

It gives Adcock Ingram great pleasure to inform you that South Africa's first infliximab biosimilar, REMSIMA®, is now available for use in rheumatology, gastroenterology and dermatology ^{1,2,3}

WITH ALMOST A DECADE OF EXPERIENCE²

with exposure reaching **24,000** patient-years treated worldwide,¹ REMSIMA® demonstrated:

- Direct and comparable long term efficacy, immunogenicity, safety and PK-PD versus originator in patients with RA inadequately responding to MTX ^{4,5}
- Direct and comparable long term efficacy versus originator in patients with AS ^{6,7}
- Effective in the induction and maintenance of clinical remission in patients with IBD ²
- REMSIMA® is generally well tolerated, with a similar safety profile to that of reference infliximab ²

REMSIMA® is approved for the same indications as reference infliximab: RA, AS, PsA, psoriasis, Crohn's disease and ulcerative colitis ²

| Product | Reg. number | Schedule | Bar Code ⁸ | Nappi code | Price (excl. VAT) | Price (incl. VAT) |
|----------------|--------------|----------|-----------------------|------------|-------------------|-------------------|
| Remsima® 100mg | 52/30.1/0309 | S4 | 6004406006493 | 3001518001 | R 3684.78 | R 4237.50 |

Our team is dedicated to providing you and your practice with not only a professional service, but access to the latest clinical and therapeutic information. You are most welcome to contact Adcock Ingram to facilitate an enquiry. We look forward to being of service to you, your practice and your patients.

Yours sincerely,

Chanel Chengan

Chanel Chengan
Marketing and Sales Manager: Biologics
Customer Care Line 0860 ADCOCK I 232625
Email: Info.Biosimilars@adcock.com

 **Remsima**[®]
Infliximab
A biological within reach



References: 1. Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health. *Biologics* 2016;44:257-266. 2. Blair HA, Deeks ED. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases. *BioDrugs* 2016;30:469-480. 3. IMS (MAT) data: May 2020. 4. Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranaukaite A, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. *Arthritis Res Ther*. 2016;18:82. doi: 10.1186/s13075-016-0981-6. 5. Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramierre E, Lanzon A, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. *Ann Rheum Dis*. 2017;76:355-363. 6. Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylonov A, Kadinov V, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. *Arthritis Res Ther*. 2016;18:25. doi: 10.1186/s13075-016-0930-4. 7. Park W, Yoo DH, Miranda P, Brzosko M, Willand P, Gutierrez-Ureña S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. *Ann Rheum Dis* 2017;76:346-354. 8. Adcock Ingram data on file. 23 March 2020.



REMSIMA® powder for concentrate for solution for infusion. Each vial contains: 100 mg infliximab. Reg. No. 52/30.1/0309. For full prescribing information refer to the package insert approved by the medicines regulatory authority, Adcock Ingram Limited. Reg. No. 1949/034385/06. Private Bag X69, Bryanston, 2021. Tel. + 27 11 635 0000. www.adcock.com 202008261041763



You have subscribed to receive digital communication from Adcock Ingram.
Should you no longer wish to receive digital communication, please reply with OPT-OUT/UNSUBSCRIBE

To report an Adverse Event, e-mail Adcock.AEReports@adcock.com or call 011 635 0134

To request a copy of the current approved package insert or references, e-mail: Helpdesk.MedicalAffairs@adcock.com

Disclaimer:

This material was presented in digital format, it is not intended for copying or distribution and remains the propriety property of Adcock Ingram.